CureVac Beheer
Beheer criteriumcontroles 2/4
CureVac's CEO is Alexander Zehnder, appointed in Apr 2023, has a tenure of 1.58 years. total yearly compensation is €978.33K, comprised of 51.1% salary and 48.9% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth $155.58K. The average tenure of the management team and the board of directors is 1.8 years and 8.7 years respectively.
Belangrijke informatie
Alexander Zehnder
Algemeen directeur
€978.3k
Totale compensatie
| Percentage CEO-salaris | 51.1% |
| Dienstverband CEO | 1.6yrs |
| Eigendom CEO | 0.03% |
| Management gemiddelde ambtstermijn | 1.8yrs |
| Gemiddelde ambtstermijn bestuur | 8.7yrs |
Recente managementupdates
Recent updates
CureVac: Back To Square One
Oct 08CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€278m |
| Mar 31 2024 | n/a | n/a | -€273m |
| Dec 31 2023 | €978k | €500k | -€260m |
Compensatie versus markt: Alexander's total compensation ($USD1.06M) is below average for companies of similar size in the US market ($USD3.24M).
Compensatie versus inkomsten: Insufficient data to compare Alexander's compensation with company performance.
CEO
Alexander Zehnder (54 yo)
1.6yrs
Tenure
€978,331
Compensatie
Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, MD & Member of Management Board | 1.6yrs | €978.33k | 0.025% $ 155.6k | |
| COO, Member of Management Board & MD | 3.3yrs | €600.74k | 0.0038% $ 23.5k | |
| Chief Scientific Officer | 1.8yrs | €614.49k | 0.0021% $ 13.1k | |
| Senior VP & Area Head of Oncology | 1.8yrs | €284.15k | geen gegevens | |
| Vice President Corporate Communications & Investor Relations | no data | geen gegevens | geen gegevens | |
| General Counsel | no data | geen gegevens | geen gegevens | |
| Head of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Head of Human Resources | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Technology | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Science & Innovation | no data | geen gegevens | geen gegevens | |
| Head of Intellectual Property | no data | geen gegevens | geen gegevens | |
| Chief Business Officer | less than a year | geen gegevens | geen gegevens |
1.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: CVAC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Scientific Director of Immunology and Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Supervisory Board Member | 5.4yrs | €96.25k | 0.0043% $ 26.6k | |
| Member of Scientific Advisory Board | 8.7yrs | geen gegevens | geen gegevens | |
| Independent Director of Supervisory Board | 1.4yrs | €51.03k | 0.0019% $ 11.6k | |
| Independent Chairman of Supervisory Board | 9.3yrs | €123.75k | 0.0075% $ 46.2k | |
| Member of Scientific Advisory Board | 8.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 8.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 8.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 8.7yrs | geen gegevens | geen gegevens | |
| Supervisory Board Member | 9.3yrs | €96.25k | 0.0048% $ 29.9k | |
| Member of Scientific Advisory Board | 8.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 8.7yrs | geen gegevens | geen gegevens |
8.7yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: CVAC's board of directors are considered experienced (8.7 years average tenure).